Glomus Vagale Tumors

NEW YORK, Nov. 22, 2022 /PRNewswire/ -- Advalight, the globally renowned company behind one of the most sophisticated dermatology lasers in the world, the ADVATx, is proud to announce one of the world's most cutting-edge, board-certified dermatologist and cosmetic surgeons, Dr. Jason Emer, as the newest partner to offer the new standard of simple to use, no downtime, non-ablative laser treatments in Beverly Hills. Continue Reading Before and After ADVATx Treatment Travis Mahan, President of ADVALight shared, "We are thrilled to partner with Dr. Emer to offer the ADVATx to address patients' skin concerns from vascular, acne and scarring to wrinkles, hyperpigmentation (including melasma) and sun damage with one of the most sophisticated lasers in the market. As an authority in anti-aging and rejuvenation treatments, Dr. Emer's endorsement of the ADVATx furthers our mission of bringing easy to use, results driven lasers with minimal downtime to patients and providers across the nation." ADVATx from Advalight combines the gold standard wavelength for eliminating vascular abnormalities with the new gold standard for non-ablative resurfacing allowing physicians and health care providers to treat 25 FDA/CE cleared indications ranging from vascular abnormalities to rosacea, acne, wrinkle reduction, melasma and hyperpigmentation on virtually all skin types. "We are excited to add the ADVATx as an offering to our practice. Throughout the years I have used my expertise in skin care, laser treatments, and surgical and nonsurgical body contouring techniques to provide my patients with the best experience and results possible. The ADVATx's immediately visible results, minimal downtime, and inclusivity of skin types makes it a great option for many patients to incorporate into their routines." - Jason Emer, MD Two of the most popular treatment options with the ADVATx include: ADVA Bright: A combination of high powered yellow and infrared laser energy that improves skin tone, texture, and overall skin health by targeting the vascular components of melasma, dyschromia, sun damage and unwanted pigment while simultaneously reducing wrinkles, limiting oil production and shrinking pore size. This treatment will ensure that you'll leave the clinic with a youthful glow to your skin. ADVA Clear: Combining pure yellow and high-powered infrared laser energy this treatment eliminates rosacea, acne, acne scars and undesired vascular abnormalities such as telangiectasia, hemangiomas and venous lakes, restoring your skin to a more youthful and healthy state. Treatments will be available at Jason Emer, MD | Beverly Hills starting December 8, 2022. ABOUT DR. JASON EMER: Dr. Emer is globally-recognized as one of the most cutting-edge, board-certified dermatologist and cosmetic surgeons in the field of advanced dermatology, plastic surgery, and body contouring, with principal offices in Los Angeles, New York City, and Boca Raton, Fla. He is also the creator of Emerage Skin. Dr. Emer specializes in head-to-toe services: Skin, Laser, Body, Face, Sensitive areas, and is world-famous for his results around sever acne, acne scarring, burns, and traumatic scars. Dr. Emer was named 'Top Doctor' by LA Magazine and has been featured by: FOX News, TMZ, Inside Edition, Entertainment Tonight, ACCESS Hollywood, The Doctors, The New York Times, PEOPLE, The Hollywood Reporter, InStyle, Cosmopolitan, Allure, Martha Stewart Living, ELLE, and Self Magazine. For more on Dr. Emer, please visit: or ABOUT ADVALIGHT Advalight is the company behind ADVATx and was founded in 2006 as a result of our founders PhD studies at the Technical University of Denmark. The company is headquartered in Copenhagen, Denmark, and has a sales and service office in San Diego, CA, USA. ADVATx is available through our network of global distributors. Scheduling Contact: Jason Emer, MD | Beverly Hills JasonEmerMD.com (424) - 441 - EMER Press Contact: Eunique Griffin The Woods & Co. [email protected] SOURCE ADVALight

Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass., Aug. 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood vessels in the peripheral vasculature. Embolization is a minimally invasive procedure intended to obstruct or reduce blood flow to an abnormality or tumor to stop hemorrhaging, reduce the size of malignant and benign tumors, and stabilize venous and arterial malformations. Recently cleared by the U.S. Food and Drug Administration (FDA), the GEM technology is a semi-solid, proprietary material packaged in a ready-to-use form, thus reducing the preparation time required for many embolization procedures. Physicians deliver the GEM agent through a catheter, and its gel-like composition enables controlled placement within patient anatomy. Unlike solid and liquid embolics that can take time to form an obstruction to blood flow, once placed, the GEM technology conforms to the targeted vasculature, immediately creating a barrier. "The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients," said Peter Pattison, president, interventional oncology and embolization, Peripheral Interventions, Boston Scientific. "This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions." The transaction is expected to be immaterial to Boston Scientific's GAAP and adjusted earnings per share in 2022. Specific terms of the transaction have not been disclosed. About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit and connect on Twitter and Facebook. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "may", "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict, including those that have emerged or have increased in significance or likelihood as a result of the COVID-19 pandemic. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document. CONTACTS: Media: Karin Dalsin +1.763.494.1914 [email protected] Investor Relations: Lauren Tengler +1.508.683.4479 [email protected] SOURCE Boston Scientific Corporation

PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic and mixed venolymphatic lesions of the skin (VM, LM and VLM, respectively), which are rare genetic vascular anomalies driven by dysregulated activation of intracellular PI3K. The data are being shared in a virtual presentation to the International Society for the Study of Vascular Anomalies (ISSVA). “People living with cutaneous VMs and LMs can experience clinical complications including pain, bleeding, and impaired functioning of the affected area. To date, their treatment options are limited to interventional procedures and surgeries. We are pleased that the trial has achieved its goal of characterizing the tolerability of a range of dosage strengths in affected patients and we believe it has provided us with the data we need to make decisions on the future direction of the program,” said Thomas Rossi, Ph.D., Chief Executive Officer of Venthera. The data presented are preliminary results from an open-label, dose-finding study of VT30 topical gel in patients with cutaneous VM/LM/VLM lesions associated with mutations that result in dysregulated PI3K activation. VT30 topical gel is designed to potently inhibit PI3K in the treated tissue without systemic side effects. Early findings include: Across 15 subjects treated in escalating-dose cohorts, VT30 topical gel has been generally well-tolerated; local self-limited rash was the only adverse experience of note, occurring at an increased incidence with the highest gel concentration. All reported adverse experiences were characterized as mild to moderate.Pharmacokinetic and pharmacodynamic skin punch biopsies were taken from within the lesion. These data demonstrate that high concentrations of drug (in the micromolar range) are present in the lesion at day 28 and show a reduction of pS6 in the lesion from baseline to day 28.No circulating drug was detected in plasma with any of the gel strengths studied. Based on the findings shared during ISSVA 2022, Venthera has tentatively selected the 0.6% gel for further study. Venthera is currently seeking partners to support development of VT30 topical gel in Phase 2. To learn more, please contact licensing@bridgebio.com. For more information about study specifics, see ClinicalTrials.gov (NCT04409145). About VentheraVenthera is dedicated to improving the lives of patients living with rare vascular anomalies by suppressing the underlying pathways that drive vascular anomaly growth. By targeting the molecular root cause of disease(s), Venthera is seeking to address unmet needs and create a new option for treating VMs, LMs, and VLMs with the hope of reducing the need for invasive and systemic treatments. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter. BridgeBio Pharma Forward-Looking StatementsThis press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to the timing and success of Venthera’s Phase 1/2 clinical trial of VT30/BBP-681 for the treatment of venous malformations, lymphatic malformations, and venolymphatic malformations associated with PIK3CA or TEK mutations, expectations, plans and prospects regarding Venthera’s regulatory approval process for VT30/BBP681, the ability of VT30/BBP-681 to treat venous malformations, lymphatic malformations, and venolymphatic malformations associated with PIK3CA or TEK mutations in humans, and the timing and success of initial top-line Phase 1/2 data of VT30/BBP-681, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, Venthera’s ability to continue and complete its Phase 1/2 clinical trial of VT30/BBP-681 for the treatment of venous malformations, lymphatic malformations, and venolymphatic malformations associated with PIK3CA or TEK mutations, past data from preclinical studies not being indicative of future data from clinical trials, Venthera’s ability to advance VT30/BBP-681 in clinical development according to its plans, the ability of VT30/BBP-681 to treat venous malformations, lymphatic malformations, and venolymphatic malformations associated with PIK3CA or TEK mutations, the extent to which Venthera identifies collaborators to support development of VT30 topical gel in Phase 2, as well as those risks set forth in the Risk Factors section of BridgeBio’s most recent Annual Report on Form 10-K and BridgeBio’s other SEC filings. Moreover, BridgeBio and Venthera operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. BridgeBio Contact:Grace RauhGrace.rauh@bridgebio.com(917) 232-5478